NATICK, Mass., May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Sterling^® SL PTA Balloon Dilatation Catheter, a high-performance balloon dilatation catheter designed for use in peripheral angioplasty procedures below the knee.  The Company plans to launch the product immediately in both markets.

The Sterling SL Balloon Catheter was developed specifically to address physicians' needs in treating below-the-knee arteries by providing a low tip profile, excellent deliverability and rapid deflation time.  It expands the Company's leading line of low-profile peripheral angioplasty balloon catheters, which includes the Sterling and Sterling ES products.  

"The introduction of the Sterling SL Balloon Catheter will provide the length options I need to address below-the-knee procedures for patients with peripheral artery disease," said Kenneth Kollmeyer, M.D., F.A.C.S., DFW Vascular Group and Chief of Vascular Surgery, Methodist Dallas Medical Center.  "This product offers the same excellent performance I have come to expect from the Sterling family of balloon catheters."

"The Sterling SL Balloon Catheter reflects Boston Scientific's commitment to providing physicians the most complete set of high-performance peripheral intervention devices," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Endovascular Unit.  "The Sterling family is the world's best selling line of low-profile peripheral angioplasty balloon catheters, and this expanded offering will help reinforce its reputation as a preferred solution for physicians treating peripheral vascular lesions."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding product performance, competitive offerings, procedural volume, overall market size and our market position.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Boston Scientific Corporation